1. Is OM-3 synergistic with GLP-2 in intestinal failure?
- Author
-
Marshall Z. Schwartz, Caitlyn M. Costanzo, and Avik Karmaker
- Subjects
Short Bowel Syndrome ,0301 basic medicine ,medicine.medical_specialty ,medicine.medical_treatment ,Absorption (skin) ,Biology ,Rats, Sprague-Dawley ,03 medical and health sciences ,0302 clinical medicine ,Gastrointestinal Agents ,Internal medicine ,Fatty Acids, Omega-3 ,Intestine, Small ,Glucagon-Like Peptide 2 ,medicine ,Animals ,Intestinal Mucosa ,Saline ,chemistry.chemical_classification ,Growth factor ,Fatty acid ,Drug Synergism ,DNA ,Glucagon-like peptide-2 ,Small intestine ,Rats ,Treatment Outcome ,030104 developmental biology ,medicine.anatomical_structure ,Endocrinology ,Intestinal Absorption ,chemistry ,030220 oncology & carcinogenesis ,Glycine ,Drug Therapy, Combination ,Female ,Surgery ,Analysis of variance ,Biomarkers - Abstract
Introduction Glucagon-like peptide-2 (GLP-2) is a known intestinal growth factor that enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR). Luminal omega-3 (OM-3) has been shown to have some growth factor properties. It is possible that their mechanisms of action differ. Thus, we hypothesized that administering these two substances together may have a synergistic effect. Methods A total of 60 adult female Sprague–Dawley rats underwent 80% MSBR and divided as follows (n = 15/group): Saline (Control) + regular feeds; GLP-2 + regular feeds; Saline + OM-3 enriched feeds; and GLP-2 + OM-3 enriched feeds. Five animals per group were sacrificed at 7, 14, and 28 days. Small intestine mucosa was harvested. DNA and protein content were measured (mucosal mass markers) at all three time points. Galactose and Glycine absorption were measured (functional capacity markers) at 28 days. Statistical analysis was done by ANOVA with post hoc Tukey's HSD test. Results At all three time points, DNA was increased in all treatment groups compared to control (P
- Published
- 2017